Richard Segal

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its upsized $1 billion aggregate principal amount of 0% convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount of notes, a figure comprising an initial $870 million aggregate principal amount of notes and the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount.

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.

Cooley advised Alarm.com Holdings, a platform for the intelligently connected property, on its $500 million convertible note offering.

Cooley advised the underwriters of Silvaco, a leading provider of technology computer-aided design (TCAD), electronic design animation (EDA) software, and session initiation protocol (SIP) solutions that enable semiconductor design and artificial intelligence through software and innovation, on its $114 million initial public offering.

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.